Table 5. Indications for lung transplant referral and listing in pulmonary vascular disease.

Referral

NYHA class III–IV symptoms during escalating therapy

Rapidly progressive disease

Use of parenteral targeted PAH therapy

Known or suspected PVOD or pulmonary capillary hemangiomatosis

Listing

NYHA class II–IV despite at least 3-month combination therapy including prostanoids

CI <2 L/min/m2

mRAP >15 mmHg

6MWD <350 m

Significant hemoptysis, pericardial effusion, or progressive RHF

NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PVOD, pulmonary veno-occlusive disease; CI, cardiac index; mRAP, mean right atrial pressure; 6MWD, six-minute walk distance; RHF, right heart failure.